| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 132, 832-838, Copyright © 1993 by Endocrine Society
ARTICLES |
TT Chuang, L Caccavelli, C Kordon and A Enjalbert
Unite 159, INSERM, Paris, France.
The role of protein kinase C (PKC) on dopamine inhibition of PRL messenger RNA (mRNA) levels was studied in anterior pituitary cells kept in primary culture. PKC was desensitized by long-term exposure to 12-O-tetradecanoylphorbol 13-acetate (TPA). Effectiveness of PKC desensitization was confirmed by the fact that after TPA pretreatment, short-term (1-h) exposure to TPA was no longer able to trigger PRL release. In contrast, the capacity of nonreceptor-mediated secretagogues as depolarization with 48 mM K+ to release the hormone was preserved. Pretreatment with TPA did not affect basal PRL mRNA levels. In contrast, it significantly reduced the dose-dependent inhibition of PRL mRNA induced by 1 nM bromocriptine after a 4-day incubation period. Since dopamine inhibition of PRL release is mediated by several second messager pathways, including cAMP, inositol phosphates, and Ca2+, we investigated whether PKC depletion was able to interact with direct stimulation of these pathways. Pretreatment with PKC suppressed stimulation of PRL mRNA levels induced by either Forskolin (FK) or 8Br-cAMP. In parallel, it reduced basal as well as FK stimulated intracellular cAMP levels. In addition, chronic exposure to TPA completely suppressed PRL mRNA inhibition induced by nifedipine, a dihydropyridine antagonist which blocks voltage-dependent Ca2+ channels. TPA desensitization also affected the action of bromocriptine, FK or nifedipine on PRL release measured under the same conditions. The data indicate that endogenous PKC can interfere with the regulation of PRL gene expression induced by both cAMP and Ca2+ pathways, two second messengers associated with the action of dopamine in lactotroph cells.
This article has been cited by other articles:
![]() |
M. Ishida, T. Mitsui, K. Yamakawa, N. Sugiyama, W. Takahashi, H. Shimura, T. Endo, T. Kobayashi, and J. Arita Involvement of cAMP response element-binding protein in the regulation of cell proliferation and the prolactin promoter of lactotrophs in primary culture Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1529 - E1537. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ben-Jonathan and R. Hnasko Dopamine as a Prolactin (PRL) Inhibitor Endocr. Rev., December 1, 2001; 22(6): 724 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hus-Citharel, N. Bouby, J. Marchetti, D. Chansel, D. Goidin, D. Gourdji, P. Corvol, and C. Llorens-Cortes Desensitization of Type 1 Angiotensin II Receptor Subtypes in the Rat Kidney Endocrinology, November 1, 2001; 142(11): 4683 - 4692. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Chuang, S.-K. Tan, L.-K. Tai, J.-P. Hsin, and F.-F. Wang Evidence for the Involvement of Protein Kinase C in the Inhibition of Prolactin Gene Expression by Transforming Growth Factor-beta 2 Mol. Pharmacol., June 1, 1998; 53(6): 1054 - 1061. [Abstract] [Full Text] |
||||
![]() |
A. Matsuno, S. Takekoshi, N. Sanno, H. Utsunomiya, Y. Ohsugi, N. Saito, H. Kanemitsu, A. Tamura, T. Nagashima, R. Y. Osamura, et al. Modulation of Protein Kinases and Microtubule-associated Proteins and Changes in Ultrastructure in Female Rat Pituitary Cells: Effects of Estrogen and Bromocriptine J. Histochem. Cytochem., January 1, 1997; 45(6): 805 - 814. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |